Skip to main content

Table 1 Parkinson’s disease and control case information from substantia nigra received from HBTRC

From: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease

 Control subjects
(70s cohort)
Control subjects
(80s cohort)
PD subjects
(70s cohort)
PD subjects
(80s cohort)
Cohort size1010108
Female (%)20.050.010.037.5
Male (%)80.050.090.062.5
Age (years)71.2 ± 2.981.6 ± 4.871.0 ± 3.381.9 ± 3.9
PMI (hours)23.0 ± 4.622.7 ± 6.516.3 ± 6.417.1 ± 6.0
Disease duration (years)N/AN/A15.3 ± 8.2a17.4 ± 8.4a
α-synuclein Braak scoreN/AN/AScore 4: n = 5
Score 5: n = 5
Score 1: n = 1
Score 3: n = 1
Score 4: n = 3
Score 5: n = 3
Tau Braak scoreN/AN/AScore 1 n = 2
Score 2: n = 5
Score 3: n = 3
Score 1 n = 2
Score 2: n = 5
Score 3: n = 1
Neuronal loss in SNScore 0: n = 10Score 0: n = 8
Score 0.5: n = 2
Score 2: n = 1
Score 3: n = 9
Score 1: n = 1
Score 2.5: n = 1
Score 3: n = 6
  1. PMI post-mortem interval. Data summarised as mean ± SD. α-synuclein Braak score (ranging from 1 to 6) based on Braak et al., 2003, Neurobiol Aging. Tau pathology Braak score (ranging from 1 to 6) based on Braak et al., 1991, Acta. Neuropathologica. Score for neuronal loss is semi-quantitative with 0 = no loss and 4 = extreme loss. aDisease duration not available for 3 cases in 70s PD cohort, and 1 case in 80s PD cohort
  2. 1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211
  3. 2. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59